Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard
South San Francisco
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Rigel's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy. In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.
296 articles with Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO).
Rigel Pharmaceuticals, Inc. announced that TAVALISSE™ (fostamatinib disodium hexahydrate) is available by prescription for the treatment of thrombocytopenia in adult patients.
Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2018.
TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
Phase 3 clinical program of TAVALISSE™ for the treatment of adults with chronic immune thrombocytopenia.
Rigel Pharmaceuticals, Inc. announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering.
Shares of Rigel Pharmaceuticals shot up about 40 percent during Thursday trading due primarily to an error on the company’s website that claimed its drug candidate Tavalisse had gained approval from the U.S. Food and Drug Administration (FDA).
When a pipe in someone’s house breaks or leaks it can cause a lot of damage to the property if it is not addressed in a timely manner. The same can be said for the pipelines of biopharma companies.
Rigel Pharmaceuticals reported a developmental setback for Tavalisse in a mid-stage kidney disease trial. Investors began dumping shares and the stock was down nearly 10 percent.
Company to host a conference call today at 8:00AM EDT to Discuss the Study Results
Rigel Pharmaceuticals, Inc. reported financial results for the fourth quarter and year end 2017.
Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America
Fostamatinib disodium is an oral investigational drug candidate designed to inhibit spleen tyrosine kinase, a key signaling component of the body's immune process that leads to platelet destruction in ITP and red blood cell destruction in AIHA.
Rigel Pharma today announced that on January 15, 2018 and January 24, 2018 the Compensation Committee of Rigel's Board of Directors approved the grants of inducement stock options to purchase an aggregate of 48,000 shares of common stock to three new employees.
The U.S. Food and Drug Administration is set to rule on Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase (SYK) inhibitor, for adult patients with chronic or persistent immune thrombocytopenia (ITP) on April 17.
More excitement should lie ahead for these small-cap biotechs this year.
Rigel Pharma today announced that on December 23, 2017 and January 2, 2018 the Compensation Committee of Rigel's Board of Directors approved the grants of inducement stock options to purchase an aggregate of 200,000 shares of common stock to twelve new employees.
Nelson Cabatuan, Rigel's vice president, finance will serve as the company's interim principal accounting officer.
Rigel today announced that on December 4, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 60,000 shares of common stock to one new employee.
Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 ASH Annual Meeting
Rigel Pharma today announced that the one-year efficacy and safety results from its FIT Phase 3 clinical program of fostamatinib for chronic or persistent immune thrombocytopenia (ITP) will be featured in an oral presentation at the 2017 ASH Annual Meeting.
These awards were granted pursuant to the Rigel PharmaInducement Plan, as amended, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.
For the third quarter of 2017, Rigel reported a net loss of $17.7M, or $0.14 per basic and diluted share, compared to a net loss of $22.6M, or $0.24 per basic and diluted share, in the same period of 2016.